Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/13/2003US20030050334 Supercritical fluid extraction of Delta-9- THC, Delta-8-THC and related cannabinoids from marijuana plants using liquid carbon dioxide as a supercritical fluid
03/13/2003US20030050333 Improved bioavailability; anticarcinogenic
03/13/2003US20030050331 Cytotoxic agents
03/13/2003US20030050329 Synergistic combination comprising roflumilast and a PDE-3 inhibitor
03/13/2003US20030050328 Methods for treating hypertension, angina, and congestive heart failure using of optically pure (-) amlodipine
03/13/2003US20030050325 Novel compounds of the indolecarboxylic family and use thereof
03/13/2003US20030050324 Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
03/13/2003US20030050323 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
03/13/2003US20030050322 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
03/13/2003US20030050320 A therapeutic agent for treating hepatitis C, based on polymerase inhibitory activity
03/13/2003US20030050318 Stable water in oil aminophylline emulsions
03/13/2003US20030050314 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050309 A gelatinase inhibitor for modulating the activity of a dopamine, serotonin, or norepinephrine receptor or transporter
03/13/2003US20030050308 Eltoprazine hydrochloride (1-(2,3-dihyro-1,4-benzodioxin-5-yl) piperazine hydrochloride), a phenylpiperazine derivative
03/13/2003US20030050307 Treating certain psychiatric and neurological disorders; anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and psychosis
03/13/2003US20030050306 Novel heteroaryl derivatives, their preparation and use
03/13/2003US20030050305 Thromboxane inhibitors, compositions and methods of use
03/13/2003US20030050304 Therapeutic compounds
03/13/2003US20030050303 Treating neutrophils and eosinophils in the tissue of the eye or nasal mucous membrane
03/13/2003US20030050302 Administering an effective amount of a benzolactam to generate soluble alpha -amyloid precursor protein and prevent beta -amyloid aggregation; treating Alzheimer's disease; antitumor agents
03/13/2003US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent
03/13/2003US20030050300 Therapeutic 5-HT ligand compounds
03/13/2003US20030050299 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050297 Administering to a mammal, a low molecular weight antioxidants, mimetics of superoxide dismutase
03/13/2003US20030050296 Photodynamic porphyrin antimicrobial agents
03/13/2003US20030050295 Treating eye disorders
03/13/2003US20030050294 Controlled release formulation for preventing or treating risk factors for cardiovascular disease
03/13/2003US20030050293 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action
03/13/2003US20030050292 Applying a hydroalcoholic gel that comprises testosterone to the skin of a male
03/13/2003US20030050291 Using trilostane or epostane with a sustained release carrier to treat diabetes mellitus, hypertension, obesity and atherosclerosis
03/13/2003US20030050290 Combination of formoterol and mometasone furoate for asthma
03/13/2003US20030050289 Combination of drospirenone and an estrogen sulphamate for HRT
03/13/2003US20030050288 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; oral contraception using multiphase progestotational agents, antiprogestins, indole or thiophene derivatives and placebo
03/13/2003US20030050287 Mixture of 2-hydroxyestrone and a substantially less amount of 17-beta estradiol
03/13/2003US20030050286 Steroids with a cyclohexene moiety are oxidized to the corresponding alpha, beta-unsaturated ketone that is converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup
03/13/2003US20030050285 Medicament
03/13/2003US20030050284 Administering to a subject before the onset of an ischemic episode at daily dosages of 1-2 g of free cdp-choline
03/13/2003US20030050283 Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye
03/13/2003US20030050281 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
03/13/2003US20030050280 Starch compositions containing biodegradation inhibitors and methods for the prevention of starch biodegradation
03/13/2003US20030050279 Beta-glucans
03/13/2003US20030050278 Agent and food for inhibiting IgE antibody
03/13/2003US20030050277 Oral skin improving agent, skin improving method, and food composition for improving skin
03/13/2003US20030050274 Dietetics or antidiabetics
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050268 Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050263 Methods and products for treating HIV infection
03/13/2003US20030050262 Inhibition of neurodegeneration
03/13/2003US20030050261 Immunostimulatory nucleic acid molecules
03/13/2003US20030050260 Method for treating diabetes by reducing in vivo cathepsin L activity
03/13/2003US20030050257 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
03/13/2003US20030050256 A sugar-modified linsidomine (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond disposed between them, deliver nitric oxide following activation by a glycosidase
03/13/2003US20030050255 An ophthalmic formulation containing an ascomycin and at least one polymer selected from ethylene oxide-propylene oxide copolymer and a crosslinked acrylic acid polymer
03/13/2003US20030050254 Derivatives of erythromycin, their preparation process and their use as medicaments
03/13/2003US20030050253 The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections such as Herpes virus infections
03/13/2003US20030050252 An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a solvent and added to a dispersion of tannic acid in the water to form the tannate salt complex
03/13/2003US20030050251 A polypeptide which inhibits or reduces tumor progression and/or metastasis
03/13/2003US20030050250 Administering an aromatic dipeptide derivative with a chemotherapeutic agent to treat tumor metastasis, solid tumor growth, angiogenesis and other neoplasia diseases
03/13/2003US20030050248 Novel amino acid and peptide inhibitors of Staphylococcus virulence
03/13/2003US20030050247 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity
03/13/2003US20030050241 Extracellular proteins, secreted proteins, membrane-bound proteins; nucleic acid molecules encoding these polypeptides, as well as vectors and host cells having those nucleic acid sequences; fusion to heterologous polypeptides; antibodies
03/13/2003US20030050240 Extracellular proteins, secreted proteins, membrane-bound proteins; nucleic acid molecules encoding these polypeptides, as well as vectors and host cells having those nucleic acid sequences; fusion to heterologous polypeptides; antibodies
03/13/2003US20030050239 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050231 Discovery of new human colon-associated polynucleotides, the polypeptides encoded by them, and antibodies that immuno-specifically bind these polypeptides; diagnosis/medical; anticarcinogenic, -metastasis agents; other colon diorders
03/13/2003US20030050229 Treatment with a 1' 2' and/or 3' nucleoside or a pharmaceutically acceptable salt or prodrug; nontoxic
03/13/2003US20030050226 Dopamine analog amide
03/13/2003US20030050224 Treatment of glial tumors with glutamate antagonists
03/13/2003US20030050222 Antineoplastic combinations
03/13/2003US20030050221 Muscarinic M1 agonist as an inhibitor of beta-amyloid (ABeta40 and ABeta42)-synthesis
03/13/2003US20030049844 Recombinant canine herpesviruses
03/13/2003US20030049820 Screening for modulators kinase activity; obtain sample, incubate with enzyme inhibitor, monitor adjustment in enzyme activity, adjustment in activity indicates modulator
03/13/2003US20030049732 Apoptosis related polynucleotides, polypeptides, and antibodies
03/13/2003US20030049725 Anti-TNF antibodies, compositions, methods and uses
03/13/2003US20030049716 Method of treating wounds by enhancing expression of procollagen
03/13/2003US20030049699 Polypeptide for use in the treatment of cell proliferation disorders
03/13/2003US20030049684 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and tumor disorders
03/13/2003US20030049662 Oligonucleotides for use in the treatment of wounds, cardiovascular, cell proliferative and developmental disorders
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049633 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/13/2003US20030049602 Detecting modulator of viral activity; obtain cell, incubate with plasmid coding viral nucleotides, recover transformed cells, incubate with viricides, monitor adjustment in expression of viral sequences, adjustment indicates viricide
03/13/2003US20030049337 Using eucalyptus plant extract
03/13/2003US20030049336 Composition and method for topical treatment of androgenic alopecia
03/13/2003US20030049334 Betel leaf extract
03/13/2003US20030049333 Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields
03/13/2003US20030049331 Mixture of loop diuretics and lithium; contact lenses
03/13/2003US20030049327 Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same
03/13/2003US20030049322 Aqueous-based pharmaceutical composition
03/13/2003US20030049321 Process for producing fine medicinal substances
03/13/2003US20030049318 Sustained release formulations of guaifenesin and additional drug ingredients
03/13/2003US20030049317 Mixture of sustained release active drug and antagonist if drug is chewed
03/13/2003US20030049315 Blending wih starch, lubricant, wetting agent; compression
03/13/2003US20030049314 Mixture of anticholesterol agent, enzyme inhibitor and aspirin
03/13/2003US20030049313 Dietary fiber delivery system
03/13/2003US20030049309 Veterinary compositions for the treatment of parasitic diseases
03/13/2003US20030049308 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication
03/13/2003US20030049307 Pharmaceutical composition
1 ... 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 ... 7860